ESR1 and neoplasm: Results of the univariate analysis showed that patients with younger age (< 50 years), higher tumor grade (grade III), larger tumor size (T2), ER-negative, PR-negative, and HER2-positive disease were more likely to receive PMRT (all P < 0.05).